Abstract PO3-05-06: Targeting PAM50 HER2-Enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer: results of the SOLTI-1502 ARIANNA trial
Year: 2024
Type: conference-abstract
Source: Cancer Research
Authors: Mafalda Oliveira, Tomás Pascual, Sonia Pernas, Mireia Margelí, Salvador Blanch, Barbara Adamo, Francisco Javier Salvador Bofill, Xavier Gonzalez-Farré, Samyukta Chillara, Patricia Galván, Esther Sanfeliu, Paula Blasco, Valeria Sirenko, Alejandra Espinosa, Charles M Perou, Aleix Prat, Luis Manso
Institutions: Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, GEICAM – Spanish Breast Cancer Group, Fundación Instituto Valenciano de Oncología, Hospital Universitario Virgen del Rocío, Instituto Oncológico Dr. Rosell, Hospital General de Catalunya, Solti, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Hospital Universitario 12 De Octubre
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4396590718